

JFW



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450, on August 26, 2004

By Juliana Hermes  
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.  
Juliana Hermes

Attorney Docket No. 78-002310US  
Client Ref. No. 21320-US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	
Veeraiah Bodepudi, et al.	Examiner: Unassigned
Application No.: 10/719,257	Art Unit: 5118
Filed: November 21, 2003	
For: DETECTABLE LABELED NUCLEOSIDE ANALOGS AND METHODS OF USE THEREOF	INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97 and § 1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:


The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0893. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Jonathan Alan Quine".

Jonathan Alan Quine, J.D., Ph.D.  
Reg. No. 41,261

QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.  
P.O. BOX 458  
Alameda, CA 94501  
(510) 337-7871  
Fax (510) 337-7877



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

10/719,257

Filing Date

November 21, 2003

First Named Inventor

Veeraiah Bodepudi

Group Art Unit

5118

Examiner Name

Unassigned

Total Number of Pages in This Submission

Attorney Docket Number

78-002310US

**ENCLOSURES (check all that apply)**☐ Fee Transmittal Form☐ Fee Attached☐ Amendment / Response☐ After Final☐ Affidavits/declaration(s)☐ Extension of Time Request☐ Express Abandonment Request☒ Information Disclosure Statement☐ Certified Copy of Priority Document(s)☐ Response to Missing Parts/  
Incomplete Application☐ Response to Missing  
Parts under 37 CFR  
1.52 or 1.53☐ Assignment Papers  
(for an Application)☐ Drawing(s)☐ Licensing-related Papers☐ Petition Routing Slip (PTO/SB/69)  
and Accompanying Petition☐ Petition to Convert to a  
Provisional Application☐ Power of Attorney, Revocation  
Change of Correspondence  
Address☐ Terminal Disclaimer☐ Small Entity Statement☐ Request for Refund☐ After Allowance Communication  
to Group☐ Appeal Communication to Board  
of Appeals and Interferences☐ Appeal Communication to Group  
(Appeal Notice, Brief, Reply Brief)☐ Proprietary Information☐ Status Letter☒ Additional Enclosure(s)  
(please identify below):1449, cited references and  
receipt acknowledgment  
postcard**Authorization to Charge Deposit Account**

Please charge Deposit Account No. 50-0893 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.

Remarks

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**Firm  
or  
Individual name

Jonathan Alan Quine, Reg. No. 41,261, Quine Intellectual Property Law Group, P.C.

Signature

Date

August 26, 2004

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.


Typed or printed name

Juliana Hermes

Signature

Date

August 26, 2004



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/719,257
Filing Date	November 21, 2003
First Named Inventor	Veeraiah Bodepudi
Group Art Unit	1637
Examiner Name	Unassigned
Attorney Docket Number	78-002310US
Date Submitted	August 26, 2004

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
	1	5,210,015	A1	Gelfand et al.	05-11-1993	
	2	5,538,848	A1	Livak et al.	07-23-1996	
	3	5,994,056	A1	Higuchi	11-30-1999	
	4	6,171,785	B1	Higuchi	01-09-2001	
	5	6,238,862	B1	McGall et al.	05-29-2001	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	6	<b>Barone et al.</b> (2001) "Novel Nucleoside Triphosphate Analogs for the Enzymatic Labeling of Nucleic Acids" <u>Nucleosides, Nucleotides and Nucleic Acids</u> 20(4-7): 1141-1145.	
	7	<b>Chauviere et al.</b> (2000) "Nucleophilic Substitution Studies on Nitrimidazoles, and Application to the Synthesis of Biologically Active Compounds" <u>J. Heterocyclic Chemistry</u> 37 (1): 119-126.	
	8	<b>Durland et al.</b> (1995) "Azole substituted oligonucleotides promote antiparallel triplex formation at non-hormopurine duplex targets" <u>Nucl. Acid. Res.</u> 23(4): 647-653.	
	9	<b>Ellis, ed.</b> (2000) <u>Chemistry of Heterocyclic Compounds</u> 36(2): 182-184.	
	10	<b>Holland et al.</b> (1993) "Detection of specific polymerase chain reaction product by utilizing the 5'—3' exonuclease activity of <i>Thermus aquaticus</i> " <u>Proc. Natl Acad. Sci. USA</u> , 88:7276-7280.	
	11	<b>Kulkarni et al.</b> (1987) "Nucleophilic Displacement of Imidazoles. I Oxygen, Nitrogen and Carbon Nucleophiles" <u>Australian J. Chemistry</u> , 40(8): 1399-1413.	
	12	<b>Kumar et al.</b> (1988) "Nonradioactive Labeling of Synthetic Oligonucleotide Probes with Terminal Deoxynucleotidyl Transferase" <u>Analytical Biochemistry</u> 169: 376-382.	
	13	<b>Mourabit et al.</b> (1996) "New C <sub>2</sub> Symmetrical and Semisymmetrical Substituted Imidazolium Ribnucleoside. Imidazolic Nucleosides Analogues" <u>Tetrahedron Asymmetry</u> 7(12): 3455-3464.	
	14	<b>Nagarajan et al.</b> (1982) "Nitroimidazoles: Part IV – 1-Sulphonyl (carbamoyl/thiocarbamoyl)-3-(1-methyl-5-nitroimidazol-2-yl)-2-imidazolidinones" <u>Indian J. Chemistry, Sect. B</u> , 21B(10): 928-	
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A-B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>	<b>Complete if Known</b>	
	Application Number	<b>10/719,257</b>
	Filing Date	<b>November 21, 2003</b>
	First Named Inventor	<b>Veeraiah Bodepudi</b>
	Group Art Unit	<b>1637</b>
	Examiner Name	<b>Unassigned</b>
	Attorney Docket Number	<b>78-002310US</b>
	Date Submitted	<b>August 26, 2004</b>

		640.	
	15	<b>Pochet et al.</b> (1990) "Synthesis and enzymatic polymerisation of 5-amino-1-(2'-deoxy-β-D-ribofuranosyl)imidazole-4-carboxamide-5'-triphosphate" <u>Nuc. Acids Res.</u> 18(23): 7127-7131.	
	16	<b>Pochet et al.</b> (1995) "Enzymatic Synthesis of 1-(2-Deoxy-β-D-Ribofuranosyl) Imidazole-4-Carboxamide, A Simplified DNA Building Block" <u>Bioorg. Med. Chem. Lett.</u> 5(15): 1679-1684.	
	17	<b>Suzuki et al.</b> (2000) "Formation of 2'-deoxyoxanosine from 2'-deoxyguanosine and nitrous acid: mechanism and intermediates" <u>Nuc. Acids Res.</u> 28(2): 544-551.	
	18	<b>Suzuki et al.</b> (2002) "Identification and Characterization of a Reaction Product of 2'-Deoxyoxanosine with Glycine" <u>Chem. Res. Toxicol.</u> 13: 227-230.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.